- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00844935
Electrocardiographic Autonomic Function Measures in Mechanically Ventilated Patients
The Value of Electrocardiographic Autonomic Nervous System Function Measures for Predicting Cardiopulmonary Recovery of Mechanically Ventilated Patients in Intensive Care
This research proposal has two main objectives. The first is to increase understanding of the underlying physiological interactions that occur between the cardiovascular, pulmonary, and ANS during transition between positive pressure mechanical ventilation (MV) and spontaneous breathing. The second is to determine if heart rate variability, (HRV) a reflection of autonomic nervous system (ANS) activity, and autonomic information flow (AIF), a set of nonlinear measures derived from HRV, both measured in the intensive care unit (ICU) can predict patient outcomes including successful weaning and in-hospital recovery time after an episode of cardiopulmonary compromise requiring MV.
Hypothesis 1. Transitions between mechanically supported ventilation and spontaneous breathing will disturb cardiovascular synchrony, altering the relationship of HRV, AIF, respiratory rate, and blood pressure;
Hypothesis 2. More normal HRV and AIF values, measured during baseline MV and sedation awakening (a period immediately prior to SBT when sedative medications are discontinued) will be associated with easier weaning, and shorter intensive care unit (ICU) and hospital lengths of stay; more abnormal measurements will be associated with longer lengths of stay;
Hypothesis 3. AIF is a more sensitive predictor of successful weaning from MV than HRV.
Study Overview
Status
Study Type
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94122
- University of California, San Francisco Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Receiving mechanical ventilation in medical-surgical intensive care unit;
- Eighteen years of age or older;
- Expectation of receiving initial spontaneous breathing trial within the next 24 hours.
Exclusion Criteria:
- Pregnant;
- Expectation of non-survival when ventilator is discontinued;
- Cardiac rhythm of atrial fibrillation;
- Paced cardiac rhythm.
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Investigators
- Principal Investigator: Barbara Drew, PhD, University of California, San Francisco
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H6052-33761-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Abnormalities
-
Ionis Pharmaceuticals, Inc.Akcea TherapeuticsCompletedAbnormalities, CardiovascularUnited States
-
University of California, DavisTerminatedAbnormalities, Cardiovascular
-
BayerCompleted
-
Soroka University Medical CenterCompletedCardiovascular Abnormalities | Hemodynamic Instability | Respiratory AbnormalitiesIsrael
-
Cliniques universitaires Saint-Luc- Université...CompletedCardiovascular AbnormalitiesBelgium
-
Medical College of WisconsinChildren's National Research InstituteCompleted
-
CargillAjinomoto Co., Inc.CompletedCardiovascular Abnormalities
-
Baylor Research InstituteActive, not recruiting
-
Washington University School of MedicineFoundation for Anesthesia Education and ResearchCompletedCardiovascular AbnormalitiesUnited States
-
Hoffmann-La RocheWithdrawnCardiovascular AbnormalitiesCanada